117 related articles for article (PubMed ID: 6498431)
1. Biochemical effects in patients with calcium oxalate stone disease during combined treatment with bendroflumethiazide and magnesium oxide.
Ahlstrand C; Tiselius HG
Br J Urol; 1984 Apr; 56(2):125-30. PubMed ID: 6498431
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of bendroflumethiazide in patients with recurrent calcium oxalate stone disease.
Ahlstrand C; Tiselius HG
J Urol; 1981 Nov; 126(5):635-9. PubMed ID: 7299925
[TBL] [Abstract][Full Text] [Related]
3. Diurnal variation of urine composition in calcium oxalate stone disease during treatment with bendroflumethiazide.
Ahlstrand C; Tiselius HG; Larsson L
Eur Urol; 1984; 10(4):260-5. PubMed ID: 6541131
[TBL] [Abstract][Full Text] [Related]
4. How are urine composition and stone disease affected by therapeutic measures at an outpatient stone clinic?
Tiselius HG; Sandvall K
Eur Urol; 1990; 17(3):206-12. PubMed ID: 2351189
[TBL] [Abstract][Full Text] [Related]
5. Urine composition in patients with urolithiasis during treatment with magnesium oxide.
Tiselius HG; Ahlstrand C; Larsson L
Urol Res; 1980; 8(4):197-206. PubMed ID: 7222314
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers.
Rattan V; Sidhu H; Vaidyanathan S; Thind SK; Nath R
Urol Res; 1994; 22(3):161-5. PubMed ID: 7992461
[TBL] [Abstract][Full Text] [Related]
7. Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis.
Kato Y; Yamaguchi S; Yachiku S; Nakazono S; Hori J; Wada N; Hou K
Urology; 2004 Jan; 63(1):7-11; discussion 11-2. PubMed ID: 14751336
[TBL] [Abstract][Full Text] [Related]
8. Magnesium excretion and calcium oxalate urolithiasis.
Resnick MI; Munday D; Boyce WH
Urology; 1982 Oct; 20(4):385-9. PubMed ID: 7147507
[TBL] [Abstract][Full Text] [Related]
9. Effect of thiazides on the urinary calcium oxalate stone-forming potential in normal males.
Brocks P; Christiansen C; Dirksen H; Transbøl I; Wolf H
Scand J Urol Nephrol; 1983; 17(3):325-8. PubMed ID: 6648380
[TBL] [Abstract][Full Text] [Related]
10. Variations in urine composition during the day in patients with calcium oxalate stone disease.
Ahlstrand C; Larsson L; Tiselius HG
J Urol; 1984 Jan; 131(1):77-81. PubMed ID: 6537822
[TBL] [Abstract][Full Text] [Related]
11. Diurnal variations of calcium, phosphorus, and magnesium in normal and calcium oxalate stone-forming urine.
Ogawa Y; Kitagawa R; Umeyama T
Nihon Jinzo Gakkai Shi; 1983 Sep; 25(9):1131-4. PubMed ID: 6686621
[No Abstract] [Full Text] [Related]
12. Calcium and magnesium metabolism during long-term treatment with thiazides.
Ljunghall S; Backman U; Danielson BG; Fellström B; Johansson G; Wikström B
Scand J Urol Nephrol; 1981; 15(3):257-62. PubMed ID: 7323748
[TBL] [Abstract][Full Text] [Related]
13. Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis.
Fetner CD; Barilla DE; Townsend J; Pak CY
J Urol; 1978 Oct; 120(4):399-401. PubMed ID: 702659
[TBL] [Abstract][Full Text] [Related]
14. [Hydrochlorothiazide, allopurinol and magnesium oxide in the treatment of recurrent calcium urolithiasis].
Musialik D; Głuszek J; Pieczyńska A
Pol Tyg Lek; 1991 Oct 7-21; 46(40-42):739-42. PubMed ID: 1669148
[TBL] [Abstract][Full Text] [Related]
15. [Relative risk periods for calcium oxalate stone formation: the circadian rhythm of formation in urine].
Deng YL
Zhonghua Wai Ke Za Zhi; 1988 Sep; 26(9):555-8, 574. PubMed ID: 3243151
[No Abstract] [Full Text] [Related]
16. Risk factors for urinary calcium oxalate crystals as revealed by their specific enzymatic assay.
Hallson PC; Rose GA
Br J Urol; 1989 Nov; 64(5):451-7. PubMed ID: 2611612
[TBL] [Abstract][Full Text] [Related]
17. Circadian variations in the risk of urinary calcium oxalate stone formation.
Robert M; Roux JO; Bourelly F; Boularan AM; Guiter J; Monnier L
Br J Urol; 1994 Sep; 74(3):294-7. PubMed ID: 7953257
[TBL] [Abstract][Full Text] [Related]
18. Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference?
Tefekli A; Esen T; Ziylan O; Erol B; Armagan A; Ander H; Akinci M
Urol Int; 2003; 70(4):273-7. PubMed ID: 12740490
[TBL] [Abstract][Full Text] [Related]
19. The composition of four-hour urine samples from patients with calcium oxalate stone disease.
Berg C; Larsson L; Tiselius HG
Br J Urol; 1987 Oct; 60(4):301-6. PubMed ID: 3690199
[TBL] [Abstract][Full Text] [Related]
20. Effect of magnesium citrate and magnesium oxide on the crystallization of calcium salts in urine: changes produced by food-magnesium interaction.
Lindberg J; Harvey J; Pak CY
J Urol; 1990 Feb; 143(2):248-51. PubMed ID: 2299712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
